NephroGenex to Host Conference Call and Webcast on Third Quarter 2015 Financial Results on Thursday, November 12, 2015

RALEIGH, N.C.--()--NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report financial results for the quarter ended September 30, 2015 on Wednesday, November 11, after the U.S. financial markets close. The Company will host a conference call and webcast the following day, Thursday, November 12, at 8:30 a.m. EST, to review third quarter results and provide an update on its PIONEER program for diabetic nephropathy and upcoming milestones.

To access the call, participants should dial 877-407-3944 (U.S. and Canada) and 412-902-0038 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed on the Events and Presentations section of the Company’s website at www.nephrogenex.com. A replay will be available on the website with the same link approximately 2 hours after the event for 30 days.

About Diabetic Nephropathy

Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease. In the Unites States there are approximately 22 million diabetic patients, 40% of whom exhibit signs of DN. Clinically, DN is characterized by a progressive increase of protein in the urine, decrease in the glomerular filtration rate, increase in serum creatinine and ultimately End-Stage Renal Disease (ESRD) requiring dialysis or a kidney transplant. Although optimal control of blood pressure and metabolic risk factors is important in decreasing the progression of diabetic nephropathy, many diabetic patients still develop overt nephropathy and reach ESRD.

About Pyridorin®

Pyridorin is an investigational compound with a distinct chemical structure that inhibits the formation of advanced glycation end-products (AGE). AGEs have been implicated in the development of diabetic nephropathy. In people with diabetes, elevated glucose reacts with proteins to form complexes that are then deposited within the kidney leading to damage that interferes with normal kidney function. AGEs also lead to the generation of highly reactive molecules such as carbonyls and reactive oxygen species that can damage both the outside of the cell and important structures within the cell.

About PIONEER

The PIONEER program is focused on the significant unmet needs of patients with diabetic nephropathy. Data from over 650 subjects from Phase 2 studies was used to support the design of the Phase 3 PIONEER-311 study in type 2 diabetic patients with overt nephropathy. The PIONEER study design was agreed with the FDA using the Special Protocol Assessment (SPA) process, a binding agreement that the protocol design, clinical endpoints, planned conduct and statistical analyses are acceptable to support regulatory approval. In addition, Pyridorin has been granted Fast Track Designation by the FDA, a process designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet medical need.

About NephroGenex, Inc.

NephroGenex (Nasdaq: NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases. Since our inception, we have collaborated with the leading scientific experts to build a portfolio of intellectual property and novel drug candidates. Our clinical program has been designed and implemented in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of Pyridorin, which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat acute kidney injury.

Contacts

Investors
The Trout Group
Michael Levitan, 646-378-2920
mlevitan@troutgroup.com
or
Media
BMC Communications
Amy Bonanno, 646-513-3117
abonanno@bmccommunications.com

Contacts

Investors
The Trout Group
Michael Levitan, 646-378-2920
mlevitan@troutgroup.com
or
Media
BMC Communications
Amy Bonanno, 646-513-3117
abonanno@bmccommunications.com